1. P102 Outcomes of coronavirus disease 2019 among patients with inflammatory bowel diseases and the influence of IBD-related medications– A Danish prospective population-based cohort study. (27th May 2021) Authors: Attauabi, M; Poulsen, A; Kajbæk Verner-Andersen, M; Rosager Hansen, M; Pedersen, N; Pilegaard Prahm, A; Berg Lødrup, A; Haderselv, K; Larsen, L; Jess, T; Glerup, H; Molazahi, A; Mathiassen Oppfeldt, A; Dahlerup, J F; Lodberg Hvas, C; Neumann, A; Wase, A; Dam Jensen, M; Nathan, T; Jensen, S Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S197 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P347 Vedolizumab as first line biologic therapy in elderly patients with contraindications against anti-TNF therapy - A real-world nationwide cohort of patients with inflammatory bowel diseases. (27th May 2021) Authors: Attauabi, M; Höglund, C; Fassov, J; Pedersen, K B; Bansholm Hansen, H; Wildt, S; Dam Jensen, M; Neumann, A; Lind, C; Albæk Jacobsen, H; Popa, A M; Kjeldsen, J; Pedersen, N; Molazahi, A; Haderselv, K; Aalykke, C; Knudsen, T; Cebula, W; Munkholm, P; Bendtsen, F Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S369 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗